<div id="readability-page-1"><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) announced its earnings results on Thursday. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.38) by $0.53, FiscalAI reports. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $268.30 million during the quarter, compared to analysts' expectations of $203.58 million.</p><h2>Apellis Pharmaceuticals Stock Down 0.3%</h2><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>Shares of NASDAQ:APLS traded down $0.11 during midday trading on Thursday, hitting $41.01. The stock had a trading volume of 8,392,532 shares, compared to its average volume of 3,822,692. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $41.14. The company has a quick ratio of 2.70, a current ratio of 3.14 and a debt-to-equity ratio of 0.98. The business's 50-day simple moving average is $30.34 and its 200-day simple moving average is $25.59. The company has a market cap of $5.25 billion, a P/E ratio of 315.49 and a beta of -0.24. </p><h2>Hedge Funds Weigh In On Apellis Pharmaceuticals</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. grew its stake in shares of  Apellis Pharmaceuticals by 23.5% in the fourth quarter. Invesco Ltd. now owns 225,976 shares of the company's stock valued at $5,677,000 after buying an additional 42,960 shares in the last quarter.  Mackenzie Financial Corp grew its stake in shares of  Apellis Pharmaceuticals by 25.4% in the fourth quarter. Mackenzie Financial Corp now owns 96,211 shares of the company's stock valued at $2,424,000 after buying an additional 19,500 shares in the last quarter.  NewEdge Advisors LLC bought a new position in shares of  Apellis Pharmaceuticals in the fourth quarter valued at $366,000.  Virtus Investment Advisers LLC grew its stake in shares of  Apellis Pharmaceuticals by 17.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 27,086 shares of the company's stock valued at $680,000 after buying an additional 4,013 shares in the last quarter.  Finally, Twinbeech Capital LP boosted its position in  Apellis Pharmaceuticals by 47.3% during the fourth quarter. Twinbeech Capital LP now owns 13,152 shares of the company's stock worth $330,000 after purchasing an additional 4,225 shares during the period. 96.29% of the stock is owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><ul><li>Are Small Caps a Harbinger of Market Declines?</li></ul><p>Several research analysts recently commented on the stock. Bank of America upgraded shares of Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $28.00 target price for the company in a report on Wednesday, January 21st. JPMorgan Chase &amp; Co.  restated a &#34;neutral&#34; rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Barclays increased their target price on shares of Apellis Pharmaceuticals from $24.00 to $41.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, April 1st. Raymond James Financial cut shares of Apellis Pharmaceuticals from a &#34;moderate buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, April 1st. Finally, Wells Fargo &amp; Company cut shares of Apellis Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and increased their target price for the stock from $26.00 to $41.00 in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of &#34;Hold&#34; and a consensus price target of $34.89.</p><p><b>Check Out Our Latest Research Report on APLS</b></p><h2>Apellis Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.  </p><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than Apellis Pharmaceuticals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

APLS

<p>Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $0.15 per share, exceeding estimates by $0.53. The company generated $268.30 million in revenue, surpassing expectations of $203.58 million. Apellis has a net margin of 2.23% and a return on equity of 8.20%. Despite the positive earnings report, shares fell 0.3% to $41.01. Analysts have mixed ratings on the stock, with a consensus price target of $34.89. The company focuses on developing therapies for rare diseases, with its lead product, Syfovre, approved for geographic atrophy.</p>

Market Beat

Apellis Pharma

Beam Therapeutics

Invesco

Bank of America

JPMorgan Chase

Barclays

Raymond James Financial

Wells Fargo

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Beats Estimates By $0.53 EPS